For most of the genomic era, the search for the causes of congenital heart defects has focused on one place: the roughly 2 percent of DNA that codes for proteins. Sequence the exome, find a broken gene, explain the disease. That approach has worked for a minority of cases and left the majority unexplained.
A study published July 9 in Science China Life Sciences went looking somewhere else. Researchers sequenced the entire genomes of 428 patients with tetralogy of Fallot and found seven variants in a stretch of DNA that codes for nothing. It is a switch, not a gene. Deleting it in the lab was enough to break the machinery that builds the vessels leaving the heart.
What Tetralogy of Fallot Is and Why TBX1 Was the Suspect
Tetralogy of Fallot is the most prevalent cyanotic congenital heart defect, occurring in roughly 3 of every 10,000 live births. It combines four features: a hole between the ventricles, obstruction of the outflow from the right ventricle toward the lungs, an aorta positioned over that hole, and thickening of the right ventricular wall. As a result, blood reaching the body carries too little oxygen, which is why affected infants can appear bluish.
A minority of cases trace to a known syndrome or chromosomal abnormality. The best-established cause is the deletion of a region on chromosome 22, known as 22q11.2, which causes DiGeorge syndrome. Within that deleted stretch sits TBX1, a transcription factor whose role in outflow tract development has been demonstrated in mice for a quarter century.
Which raises an obvious question the field had not answered. If losing TBX1 entirely causes heart defects, what about the DNA that controls how much TBX1 a developing cell makes?
Seven Variants in a Switch, Nine Percent of a Cohort
The team at Nanjing Medical University performed whole-genome sequencing on 428 patients with tetralogy of Fallot. They identified the 22q11.2 deletion, encompassing the TBX1 region, in 31 cases. Separately, they identified seven functional noncoding variants in a TBX1 enhancer, which they designated EnhTBX1.
Together, those findings accounted for 9.81 percent of the cohort, or 42 of 428 patients. The paper, first-authored by Jimiao Gao, with Zhibin Hu among the corresponding authors, presents this as evidence that noncoding variants in the TBX1 enhancer contribute to the condition.
An enhancer is a regulatory element. It carries no instructions for building a protein. What it does is bind transcription factors and dial the activity of a target gene up, often at a specific moment in a specific tissue. A variant that disrupts an enhancer can therefore leave a gene structurally perfect and functionally underpowered, which is why exome sequencing walks straight past it.
Growing the Damage in a Dish
Finding variants is one thing. Showing they matter is another, and this is where the study did something that would have been impossible a few years ago.
The researchers knocked out EnhTBX1 in embryonic stem cells and grew blood vessel organoids, three-dimensional lab-grown tissue that recapitulates vascular development. The organoids lacking the enhancer showed significantly reduced TBX1 messenger RNA, along with impaired angiogenesis, vessel regression, decreased pericyte coverage, and altered tight junction morphology.
Digging into the mechanism, the team identified TBX1 as a transcription factor specific to endothelial progenitor cells that influences their differentiation. Its main targets sit in angiogenesis pathways, including DLL4 and TGFBR2, both previously implicated in outflow tract formation.
For context on how much remains unexplained: whole-exome work has pinned NOTCH1 and FLT4 as the most common genetic contributors to non-syndromic tetralogy of Fallot, detected in about 7 percent of cases, and loss-of-function variants in ciliary genes have since been implicated as well.
Then they reversed it. Overexpressing TBX1 in the enhancer-deleted organoids restored expression of those target genes, recovered tight junction formation, and improved pericyte coverage. That rescue is what elevates the finding from correlation to a proposed causal chain.
Where This Fits in a Broader Shift
The work sits at the heart of a genuine change in how congenital heart disease genetics is being done. A 2020 analysis in Nature Genetics implicated noncoding de novo variants in congenital heart disease, and a 2024 study in the same journal systematically dissected human cardiac enhancers and the noncoding variants within them. Whole-genome sequencing costs have fallen far enough that reading the other 98 percent is routine. The bottleneck moved from sequencing to interpretation, and organoids are one answer to that bottleneck.
The limitations here are substantial. This was a single cohort of 428 patients recruited in China, and the variant frequencies may not transfer to other populations. Seven variants across 428 patients is a small number, and no replication in an independent cohort is reported. The functional work relied on complete deletion of the enhancer in stem cells, a far more severe manipulation than the point variants found in patients, so the organoid phenotype demonstrates the enhancer's importance rather than the specific effect of any individual variant.
Blood vessel organoids also model vascular development, not a whole heart. The outflow tract forms through interactions among several cell lineages, including neural crest, which an organoid does not fully reproduce. And even taken at face value, the combined findings explain fewer than one in ten cases.
Nothing here changes screening, counseling, or surgical management. Families with a child affected by a congenital heart defect should discuss genetic testing options with a cardiologist or clinical geneticist rather than drawing conclusions from a single mechanistic study.
Key Questions Answered
What is a noncoding variant?
A change in DNA that lies outside the protein-coding sequence. It can still affect disease by altering regulatory elements that control when and how strongly a gene is switched on.
What did the study find?
Seven functional noncoding variants in an enhancer controlling TBX1 among 428 tetralogy of Fallot patients. Combined with 22q11.2 deletions, these accounted for 9.81 percent of cases.
How did researchers show the enhancer mattered?
They deleted it in embryonic stem cells and grew blood vessel organoids, which showed reduced TBX1 expression, impaired vessel formation, and vessel regression. Restoring TBX1 reversed those defects.
How common is tetralogy of Fallot?
It occurs in roughly 3 of every 10,000 live births and is the most prevalent cyanotic congenital heart defect.
Does this change genetic testing today?
No. Standard clinical testing does not assess this enhancer, and the findings require replication in independent cohorts before any diagnostic use.
Why did earlier studies miss this?
Most studies of congenital heart disease genetics used exome sequencing, which sequences only protein-coding regions. Enhancers sit outside that window.
What explains the other 90 percent of cases?
Largely unknown. Whole-exome sequencing has identified NOTCH1 and FLT4 in approximately 7 percent of non-syndromic cases, and loss-of-function variants in ciliary genes have since been implicated. Other regulatory elements and non-genetic factors remain under investigation.
